Myasthenie und myasthene Syndrome: Was gibt es Neues?

J. P. Sieb

doi:10.1055/s-0032-1305253

Klinische Neurophysiologie, Table of Contents

Klinische Neurophysiologie 2012; 43(03): 177-187
DOI: 10.1055/s-0032-1305253

Fort- und Weiterbildung

Myasthenie und myasthene Syndrome: Was gibt es Neues?

Myasthenia Gravis and Myasthenic Syndromes: What’s New?

J. P. Sieb

Neurologische Klinik, HELIOS Hanseklinikum Stralsund

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Köhler W, Sieb JP. Myasthenia gravis. 4.. Aufl. Bremen: UNI-MED; 2012
2 Sieb JP. Repetitive Nervenstimulation. Das Neurophysiologie-Labor 2012; 34: 57-67
3 Jacob S, Viegas S, Leite MI et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis clustered AChR antibodies in myasthenia gravis. Arch Neurol 2012; 1-8
4 Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69: 445-451
5 Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-435
6 Farrugia ME, Robson MD, Clover L et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129: 1481-1492
7 Behin A, Mayer M, Kassis-Makhoul B et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008; 18: 443-446
8 Poulas K, Koutsouraki E, Kordas G et al. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 2012; ePub vorab: S0165-5728(12)00165-8 [pii], Doi:
9 Gomez AM, Van Den Broeck J, Vrolix K et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010; 43: 353-370
10 Cole RN, Reddel SW, Gervasio OL et al. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63: 782-789
11 Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010; 23: 530-535
12 Pasnoor M, Wolfe GI, Nations S et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41: 370-374
13 Niks EH, van Leeuwen Y, Leite MI et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008; 195: 151-156
14 Lauriola L, Ranelletti F, Maggiano N et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005; 64: 536-538
15 Diaz-Manera J, Martinez-Hernandez E, Querol L et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78: 189-193
16 Marouf W, Sieb JP. Myasthenia gravis und myasthene Syndrome. Z Rheumatol 2009; 68: 465-470
17 Leite MI, Coutinho E, Lana-Peixoto M et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology 2012; 78: 1601-1607
18 Kister I, Gulati S, Boz C et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006; 63: 851-856
19 Aarli JA. Herzmyasthenie: myasthenia of the heart. Arch Neurol 2009; 66: 1322-1323
20 Suzuki S, Utsugisawa K, Yoshikawa H et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009; 66: 1334-1338
21 Romi F, Suzuki S, Suzuki N et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012; 259: 1312-1316
22 Nagane Y, Suzuki S, Suzuki N et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011; 65: 16-22
23 Wagner S, Janzen RW, Mohs C et al. Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wochenschr 2008; 133: 2377-2382
24 Sanders DB, Hart IK, Mantegazza R et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400-406
25 The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399
26 Hehir MK, Burns TM, Alpers J et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41: 593-598
27 Yoshikawa H, Kiuchi T, Saida T et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82: 970-977
28 Heckmann JM, Rawoot A, Bateman K et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11: 97
29 Pellkofer HL, Armbruster L, Linke R et al. Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neuroimmunol 2009; 217: 90-94
30 Sieb JP, Veauthier C. Lambert-Eaton-Syndrom – Aktuelles zu Diagnose und Therapie. Klin Neurophysiol 2008; 39: 208-218
31 de Buys Roessingh AS, Loriot MH, Wiesenauer C et al. Lambert-Eaton myasthenic syndrome revealing an abdominal neuroblastoma. J Pediatr Surg 2009; 44: E5-E7
32 Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132: 129-134
33 Harms L, Sieb JP, Williams AE et al. Long-term disease history, clinical symptoms, health status and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndroms: results of a patient interview survey in Germany. Journal of Medical Economics 2012; 15: 1-10
34 Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37: 572-575
35 Oh SJ, Kurokawa K, Claussen GC et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32: 515-520
36 Baslo MB, Deymeer F, Serdaroglu P et al. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis. Neuromuscul Disord 2006; 16: 454-458
37 Oh SJ, Hatanaka Y, Claussen GC et al. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007; 35: 178-183
38 Titulaer MJ, Soffietti R, Dalmau J et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011; 18: 19-e3
39 Titulaer MJ, Klooster R, Potman M et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260-4267
40 Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; 2 CD003279
41 Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin 2010; 26: 1363-1375
42 Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902
43 Pellkofer HL, Voltz R, Kümpfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009; 40: 305-308
44 Chalk CH, Murray NM, Newsom-Davis J et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552-1556
45 Maddison P. Neuromyotonia. Clin Neurophysiol 2006; 117: 2118-2127
46 Lancaster E, Huijbers MG, Bar V et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69: 303-311
47 Irani SR, Alexander S, Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748
48 Müller JS, Herczegfalvi A, Vilchez JJ et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130: 1497-1506
49 Senderek J, Muller JS, Dusl M et al. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet 2011; 88: 162-172
50 Belaya K, Finlayson S, Slater CR et al. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet 2012; 91: 193-201
51 Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44: 789-794